TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06496945

Intervention type: OTHER
Intervention: Adult day program use
Description: Day program use patterns will be determined, using Latent Class Analysis. Three continuous variables will be categorized as low, low-moderate, high-moderate, high, using sample distribution quartiles: (1) Time between first RAI-HC assessment and first attendance of a day program, (2) average number of hours of day program attendance (i.e., total number of hours spent in a day program divided by the number of times attended), and (3) total number of days a person attended a day program.

Intervention type: OTHER
Intervention: Other community care (non-attendees)
Description: Any publicly funded continuing care services in the community, other than adult day programming (e.g., home care, in-home respite). Community care participants will be propensity score matched with day program participants, using RAI-HC variables on day program eligibility (to ensure similarity of non-attendees to day program attendees). Matching variables will include: physical functioning, cognition, behavioural symptoms, bladder/bowel continence, availability of a caregiver, and caregiver distress. The investigators will also include variables on health and social characteristics (e.g., age, sex, type/duration of publicly funded community care received before the matching index date, deprivation indices).
Study: NCT05828576

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Patients will be asked for two additional control visits in the hospital. Overview of measurements: Included subject will visit the UMCU at two occasions. The first MRI scan will be the baseline MRI, and the second MRI will take place after 2 years of follow-up. Additional follow-up data will be collected through medical records reporting on regular follow-up.
Study: NCT04175535

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Posterior Endoscopic Cervical Discectomy
Description: The most common alternative in the case of soft cervical disc herniations.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior cervical decompression and fusion
Description: The standard procedure for operation of cervical disc herniations.
Study: NCT06311188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ITR Healing intervention
Description: This is a nonrandomized test of the culturally adapted ITR healing intervention that is based on the ITR framework. The ITR Healing intervention comprises six 60-minute sessions based on Intersectionality theoretical framework, Healing Centered Engagement (HCE) activities that were integrated into the intervention, as well as participant's feedback about the intervention. Also, the participants' behavioral experiences per the Theoretical Domains Framework targets was used to adapt the intervention activities. HCE focuses on building a holistic approach and empathy for each session, i.e., using music, dance/movement, meditation, breathing and journaling.
Study: NCT05944445

Intervention type: DRUG
Intervention: Linezolid 600 mg
Description: Linezolid 600mg injection
Study: NCT06545643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dreem headband
Description: The Dreem headband is an EEG-based wearable tool that can be used to reliably assess the relationship between sleep and epilepsy over extended observation periods.
Study: NCT05509309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APERS-based model
Description: APERS-assessments followed by in-service training, APERS-feedback and on-site coaching to improve primary school classroom quality for students with ASD/SCC
Study: NCT05455619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evexomostat
Description: Evexomostat (SDX-7320) is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
Study: NCT05513846

Intervention type: DEVICE
Intervention: DREEM EEG Device
Description: The DREEM EEG device will be used to measure brain age.

Intervention type: DEVICE
Intervention: DREEM EEG Device
Description: The DREEM EEG device will be used to measure brain age.

Intervention type: DEVICE
Intervention: SleepImage Ring
Description: The SleepImage ring uses plethysmography to analyze sleep architecture and cardiopulmonary coupling.

Intervention type: DEVICE
Intervention: SleepImage Ring
Description: The SleepImage ring uses plethysmography to analyze sleep architecture and cardiopulmonary coupling.
Study: NCT04863664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation (RV Implant)
Description: Required electrical testing for pacing, sensing, impedance and defibrillation will be completed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation (LBBAP Implant)
Description: Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
Study: NCT06097741

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI sequences
Description: Ultra short / zero TE sequence on MRI being tested on healthy patients and improved by manually fine tuning the sequence
Study: NCT05666206

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fibrin sealant in hypospadias
Description: fibrin sealant will be used over the suture line

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fibrin sealant in hypospadias
Description: fibrin sealant will be used over the suture line
Study: NCT05394207

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. casei DG® (Lactobacillus paracasei CNCM I-1572)
Description: L. casei DG® (Lactobacillus paracasei CNCM I-1572) containing 8 billion of live cells daily + Vitamin D 4.000 U.I. daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The comparator product is an identical matching placebo daily + Vitamin D 4.000 U.I. daily.
Study: NCT04728815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU - Phase 1
Description: 4-8 weeks of TAU treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU - Phase 1
Description: 4-8 weeks of TAU treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU - Phase 1
Description: 4-8 weeks of TAU treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS - Phase 1
Description: 4-8 weeks of CAMS treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS - Phase 1
Description: 4-8 weeks of CAMS treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS - Phase 1
Description: 4-8 weeks of CAMS treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT - Phase 1 and 2
Description: up to 16 weeks of DBT treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS - Phase 2
Description: Up to 8 weeks of CAMS treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS - Phase 2
Description: Up to 8 weeks of CAMS treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT - Phase 2
Description: Up to 8 weeks of DBT treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT - Phase 2
Description: Up to 8 weeks of DBT treatment
Study: NCT04949776

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mammograms
Description: In the women participating in the study, two strategies for reading mammograms will be carried out:~Strategy 1: Standard reading of the program. Double independent and non-consensual reading of all cases, without any artificial intelligence system (standard strategy).~Strategy 2: Reading strategy based on the global Score granted by Transpara® (strategy based on artificial intelligence):~* In studies with a Score \<8 (studies with a low probability of cancer): They will not be evaluated by any radiologist.~* In studies with a Score\> 7 (studies with a high probability of cancer): double reading will be carried out, assisted by Transpara®.
Study: NCT06246344

Intervention type: RADIATION
Intervention: MRI Guided Simultaneous Integrated Boost Radiotherapy
Description: MRI Guided Simultaneous Integrated Boost Radiotherapy
Study: NCT05505539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Given intralesionally by injection
Study: NCT05229640

Intervention type: DEVICE
Group type: OTHER
Intervention: Fibroscan
Description: Subjects will fast for at least three hours, then have at least 10 fibroscan readings of their liver.
Study: NCT06056401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: record Hemodynamic variables, respiratory variables and arterial blood gas at specific times
Description: Hemodynamic variables, respiratory variables and arterial blood gas were measured and recorded 15 minutes after induction of anesthesia (T1), 15 minutes after establishment of a folding knife position (T2), 30 and 60 minutes after CO2 pneumoconiosis (T3 and T4), and 15 minutes after pneumoconiosis (T5). Hemodynamic variables measured included mean arterial pressure , heart rate , cardiac output, cardiac index, stroke volume index and stroke volume variation. Breathing variables include tidal volume, minute ventilation , respiratory rate , airway frontal pressure , mean airway pressure , plateaus airway pressure , peripheral oxygen saturation , oxygen saturation , and oxygen response . Arterial blood gas variables include pH value, arterial carbon dioxide, arterial oxygen pressure , alkali surplus , alveolar oxygen pressure , and bicarbonate of soda ion concentration .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: record Hemodynamic variables, respiratory variables and arterial blood gas at specific times
Description: Hemodynamic variables, respiratory variables and arterial blood gas were measured and recorded 15 minutes after induction of anesthesia (T1), 15 minutes after establishment of a folding knife position (T2), 30 and 60 minutes after CO2 pneumoconiosis (T3 and T4), and 15 minutes after pneumoconiosis (T5). Hemodynamic variables measured included mean arterial pressure , heart rate , cardiac output, cardiac index, stroke volume index and stroke volume variation. Breathing variables include tidal volume, minute ventilation , respiratory rate , airway frontal pressure , mean airway pressure , plateaus airway pressure , peripheral oxygen saturation , oxygen saturation , and oxygen response . Arterial blood gas variables include pH value, arterial carbon dioxide, arterial oxygen pressure , alkali surplus , alveolar oxygen pressure , and bicarbonate of soda ion concentration .
Study: NCT04668547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic Embryolysis
Description: Hysteroscopic removal of the products of conception for induced abortion using a hysteroscopic morcellator. If this method of induced abortion fails, a traditional Dilation and Curettage procedure is performed
Study: NCT04381533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Adolescent Community Reinforcement Approach (I-A-CRA)
Description: The intervention is a behavioral internet-based intervention based on the Adolescent Community Reinforcement Approach. The program encompasses text, pictures, videos, and written as well as practical assignments (skills training). The main components of the treatment for the young adult with problematic alcohol use consist of psychoeducation and functional analysis, goal formulation, increasing prosocial behaviors, relapse prevention, problem solving, and communication training. The accompanying significant other receives modules containing information focusing on gaining an understanding of the treatment components aimed at the young adult, as well as communication training to improve communication between the young adult and the significant other.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation, information on use of alcohol and its effects
Description: The intervention is a behavioural internet-based intervention including psychoeducation focusing on providing information on alcohol, alcohol use, and its effects. The psychoeducation is provided via texts and pictures, and there is a possibility of asking questions to a therapist if needed however no therapist contact is mandatory. There are separate programs directed towards the young adult and the accompanying significant other. The programmes give brief self-help tips at the end. The intervention approximately corresponds to the information given in a primary care setting for someone with problematic alcohol use.
Study: NCT05074394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-DROPS
Description: COVI-DROPS is a fully human monoclonal antibody that is a neutralizing antibody to SARS-CoV-2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent solution
Study: NCT05193604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2858 injection
Description: TQB2858 injection is a programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β bispecific antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsule
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine hydrochloride for injection
Description: Chemotherapy medicine for metastatic pancreatic cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin bound)
Description: Chemotherapy medicine for metastatic pancreatic cancer
Study: NCT06189066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splenic Ultrasound
Description: Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
Study: NCT06263855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CURE
Description: A large language model (LLM) to help clinicians prepare discharge summaries for hospitalized patients.
Study: NCT06424288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vicadrostat
Description: Vicadrostat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 690517
Study: NCT06228534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage with tunneling technique
Description: THIS IS THE INTERVENTION GROUP THE RECIPIENT AREA OF THE CONNECTIVE GRAFT IS PREPARED.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage with tunneling technique
Description: THIS IS THE INTERVENTION GROUP THE RECIPIENT AREA OF THE CONNECTIVE GRAFT IS PREPARED.
Study: NCT04742751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: To begin week 12 for participants who remain prediabetic after 12 week lifestyle run-in. Dosage and Route of Administration: 500 mg dose/ day to be taken orally, increased to 1000 mg dose/ day at week 14 through week 24. The dose should be taken immediately following the evening meal and at approximately the same time daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Intervention
Description: Lifestyle Change Digital Intervention - This is a digital platform that will include a core curriculum focused on diet, exercise, and behavioral strategies for goal setting and self-monitoring to improve diet including a weight loss On Day 1, participants will begin their digital lifestyle intervention using their smart-phone application with their lifestyle coach and peer group.~On day 14, participants will be contacted by phone (+/- 4 days, day 10 to 18) and adherence assessed using virtual pill counts via phone calls.~At weeks 4, 8, 16 and 20 a phone-based pill count for adherence and adverse event symptom log will be completed and study medication dispensed.~At week 12 (interim assessment) and 24 (study-end), the participant will return to St. Jude Children's Research Hospital (SJCRH) for an in-person assessment.~The digital lifestyle change program will complete at week 24.
Study: NCT06284317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant durvalumab
Description: Durvalumab is given at a fixed dose of 1500 mg i.v. every 4 weeks (±1 week) until relapse or unacceptable toxicity, for a maximum of 12 cycles after surgery.
Study: NCT06551701

Intervention type: OTHER
Intervention: Pharmacist call
Description: Pharmacists will call patients and their providers to discuss benefits of statin use
Study: NCT05860114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: Drug: ITF2357 Givinostat 10mg/mL Dose: 10mg/mL; Dosage form: oral suspension~On days 1 and 13 givinostat was administered in the morning, following an overnight fasting of at least 8 hours and subjects remained fasted until at least 4 hours post-dose. Moreover the subjects were in a semi-recumbent position and remained semi-recumbent until at least 4 hours post-dose.No fluids were allowed from 1 hour before dosing until 2 hours post-dose. Water was provided ad libitum at all other times.~From Day 5 to Day 12, subjects received givinostat 50 mg as oral suspension, twice a day, in the morning and in the evening.
Study: NCT05947331

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Graded Anderson procedure
Description: In graded Anderson proceduren only recession of yoke muscles is done.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kestenbaum procedure
Description: In Kestenbaum procedure, recession of yoke muscles and resection of their antagonists is done based on Parks table for Kestenbaum procedure according to the preoperative amount of head turn.
Study: NCT06280781

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Scans
Description: The regular use of MRI in active surveillance will lead to greater confidence in active surveillance for patients with low and medium risk prostate cancer. This is because such a strategy is likely to detect cancer progression earlier with fewer invasive biopsies. Those patients randomised to the intervention arm will have additional MRI scans. These will be non-contrast so there is no risk from having repeated 1-2 yearly injections of gadolinium contrast. Patients with contraindications to MRI will not be taking part in the study so will not be exposed to an unnecessary MRI.~Patients with a visible lesion or medium risk cancer will have PSA 6 monthly and MRI annually. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5. In all patients, a targeted biopsy will be carried out if the MRI PRECISE score is \>/=4.
Study: NCT05947110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric-based hydro-kinesio therapy
Description: The plyometric-based hydro-kinesio therapy was conducted for 45 minutes, twice weekly, for 8 successive weeks. The training was geared toward the lower body and was conducted under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise therapy
Description: The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for 8 successive weeks.
Study: NCT02312518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRP Concepts Fibrin Bio-Matrix
Description: PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual and Customary Practice
Description: Usual and Customary Practice for non-healing venous leg ulcers

Intervention type: OTHER
Group type: OTHER
Intervention: Usual and Customary Practice
Description: Usual and Customary Practice for non-healing venous leg ulcers
Study: NCT05109338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ben-Guard Garment
Description: Wearable device designed to secure CVCs and gastrointestinal feeding tubes. The Ben-Guard Catheter Securement Device was designed specifically to better secure and conceal CVC tubing, protecting the patient by keeping tubing closer to the body.
Study: NCT05058040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oligomannate Capsules
Description: Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
Study: NCT05819476

Intervention type: PROCEDURE
Group type: OTHER
Intervention: OLP-injection
Description: Open-label placebo injections without any active ingredient (5 ml 0.9% saline). All participants will be informed that the administered injections are placebo infusions.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: OLP-injection
Description: Open-label placebo injections without any active ingredient (5 ml 0.9% saline). All participants will be informed that the administered injections are placebo infusions.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: OLP-injection
Description: Open-label placebo injections without any active ingredient (5 ml 0.9% saline). All participants will be informed that the administered injections are placebo infusions.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: OLP-injection
Description: Open-label placebo injections without any active ingredient (5 ml 0.9% saline). All participants will be informed that the administered injections are placebo infusions.
Study: NCT06117878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK510
Description: NK510 will be administered through intravenous infusion.once a week，for a total of six times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK510
Description: NK510 will be administered through intravenous infusion.Twice infusions on week 1,week 3,week 5 respectively.
Study: NCT05819476

Intervention type: PROCEDURE
Group type: OTHER
Intervention: OLP-injection
Description: Open-label placebo injections without any active ingredient (5 ml 0.9% saline). All participants will be informed that the administered injections are placebo infusions.

Intervention type: OTHER
Group type: OTHER
Intervention: Scripted Evidence-based treatment rationale
Description: As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP. In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.